Stock Market

Shares of BioCryst Pharmaceuticals spiked 19% after the biotech company won US regulatory approval for Orladeyo, (berotralstat), its lead drug candidate for the prevention of attacks in hereditary angioedema (HAE) patients. BioCryst (BCRX) said that the US Food and Drug Administration (FDA) approved the oral, once-daily Orladeyo as a treatment to prevent attacks of hereditary

Ulta Beauty missed analysts’ sales expectations for the third quarter of fiscal 2020 (ended Oct. 31) and issued a weak fourth-quarter outlook as the coronavirus pandemic continues to hurt the cosmetics retailer’s operations. Shares declined 3.5% on Dec. 4. The company’s 3Q net sales fell 7.8% year-over-year to $1.55 billion with comparable sales down 8.9%.

Amazon (AMZN) kicked off its 9th annual AWS (Amazon Web Services) re:Invent conference on Monday with a keynote speech by AWS CEO Andy Jassy. As the event was virtual, RBC analyst Mark Mahaney logged in to get the lowdown and logged out “incrementally positive about the opportunity given AWS’s immense scale, market leadership, continued customer

by confoundedinterest17 Call option volume has soared with The Fed’s endless monetary easing. But it isn’t just call option volumes that increased with The Fed’s balance sheet, but the S&P 500 index and commercial real estate have increased as well. Home prices and mortgage originations have also soared with Fed stimulus. We now have an economy

Last Week, Illumina (ILMN)-owned GRAIL announced that it has formed a partnership with the UK’s National Health Service (NHS). Starting in 2021, GRAIL’s multi-cancer early detection blood test Galleri will become available to UK patients. The program will initially screen 165,000 patients, but that figure could rise to 1 million by 2024-25 and consequentially expand

Food Bank for New York City distributes turkeys and Thanksgiving fixings with support from Stop & Shop and WBLS’ The Steve Harvey Morning Show on November 16, 2020 in New York City. Michael Loccisano | Getty Images Entertainment | Getty Images Job growth slowed significantly in November and looks set to decline even more, as

via rushlimbaugh: RUSH: The next 10 days are crucial, ladies and gentlemen. Do not get mad at me here. I’m just… You could disagree with me all you want. You may think that I’m not right about this, and you might want to say, “What do you know? You haven’t even been here in a week

Is the long-awaited turnaround finally in the cards for Blackberry (BB)? The stock has been on a multiyear downtrend, unable to halt the slide since its glory years as a smartphone giant. However, BlackBerry stock gained traction this week with shares rising 45% in the past four trading sessions. The uptick came following an announcement

A customer exits a Big Lots store in Clifton, New Jersey. Emile Wamsteker | Bloomberg | Getty Images Check out the companies making headlines in midday trading. Big Lots — The retail stock sank 9% after the company declined to give guidance as part of its third-quarter earnings report. Big Lots beat analyst expectations on

There’s just no pleasing the market sometimes. On Monday, Zoom (ZM) dialed in another strong quarterly statement, only to see its share price drop by 15% in the following session. It has been a breakout year for the video conferencing platform, but investors were evidently nonplussed by the size of the latest beat and raise,

Traders work on the floor of the New York Stock Exchange. NYSE Stimulus to help the economy and vaccines to stop the virus are expected to the be the main focus in markets in the week ahead.  Efforts to move along a fiscal package in Congress picked up momentum in the past week with Congressional

by Kimble Charting It’s been 20 years since the last major peak in the US Dollar. Could the greenback’s latest turn lower confirm another peak? Today’s chart takes a macro view of the US Dollar Index and highlights the long-term down-trend at each point (1). As you can see, the buck is on a topsy turvy ride,

With markets generally rising for now – the S&P is up over 9% in the past 30 days – investors are taking a close look at growth stocks. These are the equities that show long-term appreciation, with returns to investors based mainly on share price gains. It’s an obvious move to make, when the mood

Check out the companies making headlines before the bell Friday: Ollie’s Bargain Outlet (OLLI) — Shares of the retailer slid more than 11% following commentary around a slowdown in the company’s fourth-quarter trends. “Quarter-to-date, our comparable-store sales increases are tracking in the low single-digits,” CEO John Swygert said in a statement. Goldman Sachs downgraded the

Recent numbers reported by Nio, Xpeng and Tesla clearly indicate the growing demand for electric vehicles, driven by technological advances and favorable sustainability policies. EV adoption is increasing and Goldman Sachs now expects EVs to account for 18% of global new light vehicle sales in 2030 and speed up to 29% in 2035. Goldman Sachs

Job gains in November are expected to be weaker than in October, reflecting the impact of virus-related shutdowns by states and local governments due to the record spread of Covid-19. Economists expect a consensus of 440,000 nonfarm payrolls were added in November, and the unemployment rate fell to 6.7% from 6.9%, according to Dow Jones.

Today will be a make or break day for BioCryst Pharmaceuticals’ (BCRX) lead drug candidate. Orladeyo, (berotralstat), the biotech’s oral treatment for the prevention of hereditary angioedema (HAE) attacks will face an FDA approval decision. A rare disease defined by unpredictable and possibly life-threatening periodic swelling attacks, hereditary angioedema affects approximately one in 50,000 people.

Fans gather at local Ulta Beauty in Houston to greet Kylie Jenner at the launch of her cosmetics line on November 18, 2018 in Houston, Texas. Rick Kern | Getty Images Check out the companies making headlines after the bell:  DocuSign — Shares of DocuSign popped 6% after the electronic-documents company posted better-than-expected results for

by David Haggith Want to see a crystal-clear picture of who has been helped the most by decades of trickle-down economics, who has gone nowhere and who has actually gone slightly downhill? Well, here you go: Everyone has gone essentially nowhere, except the top 10%. Clear proof that throughout the years of trickle-down economics (primarily created by huge

Shares of Tesla jumped more than 4% in Thursday’s pre-market session after Goldman Sachs upgraded the electric vehicle maker’s stock to Buy from Hold and ramped up the price target to a Street high of $780.   “We believe that the shift toward battery electric vehicle (EV) adoption is accelerating and will occur faster than

Youtube.com does the playback error.Then bitchute.com loads the video and says its playing. But it is not playing.This is the 3rd simultaneous censorship tool being used in the past 2 months. Exactly the same, like clock work. And it happens at night 1PM. Every time. Zero Day exploit. Or ddos attack on the video servers

Shares of Snowflake dropped 3.7% in Wednesday’s extended trading as the cloud-based data-warehousing company reported on a wider-than-expected loss in the third quarter. The company posted a 3Q loss per share of $1.01, while analysts were expecting a loss of $0.27. However, the quarterly loss narrowed from the year-ago’s loss of $1.92 per share. Meanwhile,

BY SVEN HENRICH As $SPX is trying for a new high here and $ES futures are retesting the highs from November 9th I thought I may chime in with a few thoughts here. Firstly, in general the bull price target outlined in October has barely been penetrated, but it may well be in the days ahead as

We all want to be rid of the coronavirus, of course – and when it fades, the general economy is expected to bounce back. Getting to specifics, Credit Suisse Chief U.S. Equity Strategist Jonathan Golub sees economic momentum moderating post-pandemic, and sets a one-year target for the S&P 500 of 4,050, or 10.5% above current

Thank you to our readers! November was another record month at The Gateway Pundit with over 125 million page views. This is the 9th time this year we have broken all-time monthly traffic records. The Gateway Pundit climbed to number 104 in the Alexa rankings for top websites in the US. The Gateway Pundit is now listed above USA

Check out the companies making headlines in midday trading.  Palantir — The tech company slid more than 10% after Morgan Stanley downgraded the stock to underweight. The firm said Palantir now trades at a “significant premium” to its peers following shares’ more than 100% jump since the company went public on Sept. 30. Tesla —

Tesla Inc.’s billionaire founder Elon Musk said that the electric car maker would be open to talks about a friendly merger with a rival vehicle maker. Shares dropped 4.3% to $559.50 in Wednesday’s pre-market trading. At an Axel Springer event in Berlin, where Musk received an award, he was asked by CEO Mathias Döpfner if

Check out the companies making headlines before the bell Wednesday: Pfizer (PFE), BioNTech (BNTX) — Shares of Pfizer and BioNTech rose 3.4% and 5.8%, respectively, in the premarket after the U.K. approved the Covid-19 vaccine designed by the two companies. The rollout is expected to begin next week, with elderly people and medical workers first

By Glen Carrick Morgan Stanley recently raised their rating on Tesla (NASDAQ:TSLA)  for the first time in 3 years. Two weeks later and the stock has already smashed through their $540 price point, and it’s still rising. But the real news here isn’t about Tesla, or even about EVs… it’s much, much bigger than that. What it means is

Shares of Inter Parfums slipped 2.2% in Tuesday’s extended market trading after the perfume and cosmetics maker reported lower-than-expected guidance for 2021. Inter Parfums (IPAR) projects its 2021 sales to be in the range of $610 million – $625 million, missing analysts’ estimates of $669.8 million. Meanwhile, it expects earnings in the range of $1.20